Valo Health

David Berry, CEO and founder, retains majority control. The board includes representatives from Flagship Pioneering and Google Ventures. Major strategic decisions, including partnerships and capital raises, require board approval.

Valo is a biotech company wrapped in an AI platform — it develops its own therapeutic candidates internally but uses its Opus computational platform as the primary discovery tool. It does not operate a traditional wet-lab, instead relying on external contract research organizations for experimental validation.

Valo's approach centers on using 'human data' — clinical records, genomic datasets, and real-world evidence — to train its models, rather than purely public molecular databases. This integration of population-scale data with proprietary ML models is a distinguishing structural choice.

As of early 2024, Valo had not yet advanced a wholly-owned candidate into Phase 1 trials. Its most advanced program, a collaboration with Bristol Myers Squibb for oncology targets, was in preclinical stages. The firm's near-term revenue comes from partnership payments and milestone fees, not product sales.

Yes, the Valo Health Foundation is a separate 501(c)(3) entity focused on health equity and expanding access to AI-driven diagnostics in underserved populations. It is funded through a portion of Valo's corporate profits and is governed by an independent board.

Valo was founded by a former Flagship partner and is partially backed by Flagship's early-stage venture funds, but it operates as an independent company with its own board and financing. It is not a Flagship portfolio company in the traditional sense, though Flagship retains a board seat.

Valo's pipeline focuses on oncology (particularly immuno-oncology), cardiovascular disease, and neurodegenerative conditions (Alzheimer's, tauopathies). The firm has also explored metabolic diseases through the Novo Nordisk collaboration. Respiratory and rare diseases are secondary areas of interest.